{"id":"NCT02434328","sponsor":"Alcon Research","briefTitle":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 2","officialTitle":"A Two-year, Randomized, Double-masked, Multicenter, Two-arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects With Neovascular Age-related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-28","primaryCompletion":"2017-04-05","completion":"2018-03-08","firstPosted":"2015-05-05","resultsPosted":"2019-10-31","lastUpdate":"2025-01-16"},"enrollment":1048,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Neovascular Age-Related Macular Degeneration","Choroidal Neovascularization"],"interventions":[{"type":"DRUG","name":"Brolucizumab ophthalmic solution","otherNames":["RTH258"]},{"type":"DRUG","name":"Aflibercept ophthalmic solution","otherNames":["EYLEAÂ®"]}],"arms":[{"label":"Brolucizumab 6 mg","type":"EXPERIMENTAL"},{"label":"Aflibercept 2 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection (6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.","primaryOutcome":{"measure":"Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye","timeFrame":"Baseline, Week 48","effectByArm":[{"arm":"Brolucizumab 6 mg","deltaMin":6.9,"sd":11.47},{"arm":"Aflibercept 2 mg","deltaMin":7.6,"sd":12.47}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["39033924","34968756","33207259","30986442"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":79,"n":370},"commonTop":["Nasopharyngitis","Neovascular age-related macular degeneration - Fellow eye","Visual acuity reduced - Study eye","Cataract - Study eye","Hypertension"]}}